Cardiac Marker Testing Market: Rising Cardiovascular Disease Burden and Point-of-Care Diagnostics Drive Global Industry Growth

According to Kings Research, the global Cardiac Marker Testing Market was valued at USD 5.11 billion in 2024 and is projected to grow from USD 5.54 billion in 2025 to USD 10.56 billion by 2032, registering a CAGR of 9.65% during the forecast period. The market is driven by increasing cardiovascular disease incidence, rapid diagnostic technologies, and expanding healthcare infrastructure.

Market Overview

Cardiac marker testing involves measuring biomarkers released into the bloodstream when the heart muscle is damaged or under stress. These tests play a critical role in emergency medicine, intensive care units, and routine cardiovascular diagnostics.

Major biomarkers include:

• Troponin I and Troponin T
• Creatine Kinase-MB (CK-MB)
• Brain Natriuretic Peptide (BNP)
• Myoglobin
• High-sensitivity C-reactive Protein (hs-CRP)
• Other cardiac biomarkers

Key products include:

• Reagents & Kits
• Instruments

Major end users include:

• Hospitals
• Diagnostic Laboratories
• Point-of-Care Testing Facilities
• Academic & Research Institutions

These diagnostic tests enable early intervention, improve patient outcomes, and support timely clinical decision-making.

Rising Cardiovascular Disease Burden Drives Market Growth

The growing incidence of cardiovascular diseases worldwide remains the primary driver for the Cardiac Marker Testing Market.

Major growth factors include:

• Increasing heart attack cases
• Rising prevalence of heart failure
• Aging global population
• Lifestyle-related cardiovascular disorders
• Growing awareness of preventive healthcare
• Expansion of emergency care services

Healthcare providers are increasingly utilizing cardiac biomarker testing to enable faster diagnosis and treatment of life-threatening cardiac conditions.

Growing Demand for Point-of-Care Testing

Point-of-care testing has emerged as one of the strongest growth drivers for the market.

Its advantages include:

• Faster diagnosis
• Reduced laboratory turnaround time
• Immediate treatment decisions
• Improved emergency care
• Better accessibility in remote areas
• Enhanced patient management

Portable cardiac marker testing devices are becoming increasingly popular in emergency departments, ambulances, and outpatient clinics due to their ability to deliver results within minutes.

Troponin Biomarkers Lead the Market

According to Kings Research, the Troponins I and T segment generated USD 1.65 billion in revenue in 2024.

Troponins remain the preferred cardiac biomarkers because they provide:

• High diagnostic accuracy
• Early detection of myocardial injury
• Excellent sensitivity
• High clinical reliability
• Better risk stratification
• Improved treatment planning

These biomarkers have become the gold standard for diagnosing acute myocardial infarction.

Reagents & Kits Dominate Product Demand

According to Kings Research, the Reagents & Kits segment is projected to reach USD 7.35 billion by 2032.

Growth is supported by:

• Increasing testing volumes
• Frequent reagent replacement
• Rising hospital demand
• Expansion of diagnostic laboratories
• Growing point-of-care testing adoption

Reagents and kits continue to account for the largest share of the market due to their recurring use in diagnostic procedures.

Myocardial Infarction Remains the Largest Indication

According to Kings Research, the Myocardial Infarction segment accounted for 35.55% of the market in 2024.

Growing demand is driven by:

• Increasing heart attack incidence
• Emergency department admissions
• Need for rapid diagnosis
• High clinical dependence on cardiac biomarkers
• Improved survival through early intervention

Rapid biomarker testing plays a vital role in reducing treatment delays and improving patient outcomes during acute cardiac events.

Emerging Market Trends

Expansion of Point-of-Care Diagnostics

Healthcare providers are rapidly adopting compact, portable testing devices capable of delivering cardiac biomarker results within minutes. This trend is improving patient management, particularly in emergency departments and remote healthcare settings.

Integration of Artificial Intelligence

AI-powered algorithms are increasingly being integrated into cardiac marker testing platforms to improve diagnostic accuracy, automate result interpretation, identify complex biomarker patterns, and support clinical decision-making.

High-Sensitivity Cardiac Biomarkers

Manufacturers are developing high-sensitivity troponin assays capable of detecting even minor cardiac injury at earlier stages, enabling faster diagnosis and more effective treatment planning.

Digital Healthcare Integration

Modern diagnostic systems increasingly integrate with electronic health records (EHRs), cloud platforms, and hospital information systems to improve workflow efficiency, data accessibility, and long-term patient monitoring.

Market Challenges

High Cost of Advanced Assays

According to Kings Research, one of the major challenges is the high cost associated with advanced high-sensitivity cardiac biomarker assays and sophisticated diagnostic instruments. Cost constraints and limited reimbursement policies can restrict adoption in resource-limited healthcare settings.

Limited Access in Developing Regions

Healthcare infrastructure limitations and insufficient laboratory capabilities in developing countries continue to hinder widespread adoption of advanced cardiac marker testing technologies. Manufacturers are addressing this challenge through affordable point-of-care solutions and strategic partnerships.

Market Segmentation

According to Kings Research, the Cardiac Marker Testing Market is segmented as follows:

By Biomarker

• Troponins I & T
• Creatine Kinase-MB (CK-MB)
• Brain Natriuretic Peptide (BNP)
• Myoglobin
• High-sensitivity C-reactive Protein (hs-CRP)
• Others

Troponins remain the dominant biomarker segment due to their superior diagnostic accuracy.

By Product

• Reagents & Kits
• Instruments

Reagents and kits continue to lead the market because of their recurring demand in diagnostic testing.

By Indication

• Myocardial Infarction
• Heart Failure
• Acute Coronary Syndrome
• Other Cardiovascular Disorders

Myocardial infarction represents the largest application segment due to the need for rapid diagnosis in emergency settings.

By End User

• Hospitals
• Diagnostic Laboratories
• Point-of-Care (POC) Facilities
• Academic Institutions

According to Kings Research, the Point-of-Care (POC) Facilities segment is projected to register the fastest growth, with a CAGR of 10.74% during the forecast period.

Regional Analysis

North America

According to Kings Research, North America accounted for the largest market share of 38.42% in 2024, with a valuation of USD 1.96 billion.

Regional growth is supported by:

• Advanced healthcare infrastructure
• High cardiovascular disease prevalence
• Strong adoption of diagnostic technologies
• Significant healthcare expenditure
• Presence of leading diagnostic companies

The United States remains the dominant contributor to regional growth.

Asia-Pacific

Asia-Pacific is expected to witness the fastest growth, with a projected CAGR of 11.80% during the forecast period.

Growth is driven by:

• Expanding healthcare infrastructure
• Rising cardiovascular disease burden
• Increasing healthcare investments
• Growing awareness of early diagnosis
• Improving access to diagnostic services

China, India, Japan, and South Korea continue to invest heavily in advanced diagnostic technologies.

Europe

Europe maintains a significant market share due to well-established healthcare systems, increasing adoption of high-sensitivity cardiac biomarker testing, and favorable reimbursement policies for cardiovascular diagnostics.

Competitive Landscape

The Cardiac Marker Testing Market is highly competitive, with companies focusing on high-sensitivity assays, AI-enabled diagnostics, point-of-care testing platforms, and strategic collaborations.

Major market participants include:

• Abbott
• F. Hoffmann-La Roche Ltd
• Siemens Healthineers
• Danaher Corporation
• bioMérieux
• BD
• Beckman Coulter, Inc.
• Bio-Rad Laboratories, Inc.
• Thermo Fisher Scientific Inc.
• QuidelOrtho Corporation
• Agilent Technologies, Inc.
• Fujifilm Group
• DiaSorin S.p.A.
• PerkinElmer
• Randox Laboratories Ltd.

These companies continue investing in innovative biomarker technologies, digital diagnostics, and global distribution expansion to strengthen their market positions.

Future Outlook

The outlook for the Cardiac Marker Testing Market remains highly promising as cardiovascular diseases continue to pose a significant global health challenge. Increasing adoption of point-of-care diagnostics, high-sensitivity biomarker assays, artificial intelligence, and integrated digital healthcare platforms is expected to transform cardiac diagnostics over the coming years. Continuous innovation in portable testing systems and personalized cardiovascular care will further drive market expansion.

Conclusion

The Cardiac Marker Testing Market is poised for strong long-term growth, driven by the rising prevalence of cardiovascular diseases, increasing demand for rapid diagnostics, and continuous technological advancements in biomarker testing. Troponin-based assays remain the gold standard for detecting myocardial injury, while point-of-care testing and AI-powered diagnostic platforms are improving the speed and accuracy of clinical decision-making. As healthcare systems worldwide prioritize early diagnosis and timely intervention for cardiac conditions, the market is expected to witness sustained growth throughout the forecast period.